Back to Search
Start Over
Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals
- Source :
- Biomedicine & Pharmacotherapy. 69:233-236
- Publication Year :
- 2015
- Publisher :
- Elsevier BV, 2015.
-
Abstract
- The relationship between hepatic tolerance and hepatitis C virus (HCV) co-infection has not been extensively studied in clinical practice. We assessed the efficacy and safety of raltegravir-based therapy in an Italian cohort of HIV/HCV co-infected patients. One hundred and forty patients with HIV/HCV co-infection initiating raltegravir from SCOLTA project (Surveillance Cohort Long-Term Toxicity Antiretrovirals) were examined. Of them, 43 were women, with mean age of 45.4. ±. 6.4. years; 65 (46%) had undetectable HIV-RNA. < 50. copies/mL and 75 (54%) HIV-RNA. ≥. 50. copies/mL. According to CDC classification, 49 (35%) were in stage C. Based on Fib4 score at the time of starting raltegravir, patients were classified in class I in 41 cases, class II in 68 and in class III in 31 cases. Globally, the Fib4 score slightly decreased during 24. months follow-up, from 2.2 to a value of 1.8. Hepatic adverse events of any grade were observed in 67 patients, of which only 2 cases (3%) had severe liver toxicity (grade 3-4). Only one patient had to discontinue the therapy because of adverse events. According to univariate analysis, being in CDC stage C represented a risk for the development of liver toxicity, with a hazard ratio (HR) of 2.27 (95% CI 1.06-4.84, P= 0.033). None of the other variables considered (age, sex, years since detection of HIV and HCV-RNA detectable, years of previous HIV therapy, concomitant therapy with PI or NRTI, CD4+ cell count, Fib4, and transaminases level at baseline) resulted statistically correlated to the outcome. In conclusion, raltegravir-based regimens can be safely used in HCV infected patients; in this study, the hepatic toxicity has been found to be more frequent in patients with an advanced HIV disease (CDC stage C), independently of HIV-RNA suppression at raltegravir initiation.
- Subjects :
- Male
HIV Infections
medicine.disease_cause
Hepatitis
Cohort Studies
HIV Infection
Viral
Pyrrolidinone
Univariate analysis
Coinfection
Hazard ratio
virus diseases
Alanine Transaminase
General Medicine
Middle Aged
Tolerability
Hepatitis C
Pyrrolidinones
Liver
HCV
Cohort
RNA, Viral
Female
Safety
Human
medicine.drug
medicine.medical_specialty
Efficacy
Hepatitis C virus
Hepatiti
Follow-Up Studie
Raltegravir Potassium
Internal medicine
medicine
Humans
Aspartate Aminotransferases
Adverse effect
Demography
Pharmacology
business.industry
Aspartate Aminotransferase
medicine.disease
Raltegravir
Immunology
RNA
Cohort Studie
Follow-Up Studies
business
Subjects
Details
- ISSN :
- 07533322
- Volume :
- 69
- Database :
- OpenAIRE
- Journal :
- Biomedicine & Pharmacotherapy
- Accession number :
- edsair.doi.dedup.....38c425742afe1b7cd535eeb52aef9f6a